BioROSA Technologies is developing a blood test that analyzes specific biomarkers to accurately detect Autism Spectrum Disorder (ASD) in children as young as 18 months. This early detection enables timely behavioral interventions, improving language, social skills, and cognitive outcomes for affected children.
Funding
$745K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The average age of Autism Spectrum Disorder (ASD) diagnosis is four years old, despite parents often suspecting issues as early as 12 months. Currently, there is a lack of broad-based molecular diagnostic tests available for clinicians to assess ASD risk in young children. This delayed diagnosis can hinder timely access to early intervention services.
Solution
BioROSA Technologies is developing a blood test designed to detect ASD in children as young as 18 months by analyzing specific biomarkers. The test utilizes a standard blood draw to measure a panel of biomarkers predictive of ASD. Proprietary computer algorithms analyze the biomarker data to generate an ASD risk score. A positive test result enables earlier access to behavioral interventions, which can improve language, social skills, and cognitive outcomes for children with ASD.
Target Audience
The primary target audience includes pediatricians, clinicians, and parents seeking early and accurate methods for assessing ASD risk in children.
Features
- Utilizes a small blood sample obtained through a standard blood draw procedure.
- Measures a specific set of blood biomarkers that are indicative of ASD.
- Employs proprietary computer algorithms to analyze biomarker data.
- Provides a risk score for ASD based on the algorithmic analysis.